Biotech Showcase 2019: F2G Accelerates Phase IIb Program Vs Life-Threatening Fungal Infections

 
• By Mike Ward

Ian Nicholson, CEO of F2G, updated Mike Ward during Biotech Showcase 2019 on the progress the biotech company is having with its orotomide compound olorofim in a global open-label study for difficult-to-treat invasive fungal mold infections.

Video interview
• Source: Shutterstock

More from Business

More from Scrip